bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-07-04: Transition from a pre-malignant lesion to cancer does not require stemness of the cancer-originating cells in the lesion
Authors: Bu W , Li Y 
Published: March 2017

Abstract
The precancerous lesion is the final step before malignancy, and is thus a key step to cancer prevention. Precancerous lesions are heterogeneous harboring distinct subsets of cells from stem cells to differentiated cells. Whether the stem cells or other subsets in these precancerous lesions are responsible for the eventual cancer remains unanswered. Here, we report that in the precancerous lesions of the MMTV-Wnt1 model of basal-like breast cancer, there exist the stem cell-enriched keratin 6a+ subset and more differentiated WAP+ cell subset. We demonstrate that both mutated Ras and B-Raf can robustly transform both cell subsets into cancer. These data suggest that multiple cell subsets in precancerous early lesions can evolve into cancer. This finding indicates that cancer prevention should target both self-renewing cells and other cell subsets in developing precancerous lesions in high-risk individuals.
Citation Format: Bu W, Li Y. Transition from a pre-malignant lesion to cancer does not require stemness of the cancer-originating cells in the lesion [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-07-04.
Abstract P5-07-09: Stem cell-like transcriptional reprogramming in metastatic resistance
Authors: Pujana MA , Mateo F , Arenas EJ , Gomis R 
Published: March 2017

Abstract
Whether an aggressive phenotype is promoted through adaptation or resistance to target inhibition remains poorly understood. Here, complementary studies in human tumors, xenograft models and cell lines reveal transcriptional reprogramming that supports metastasis in response to PI3K/mTOR inhibition. This feature is driven by stem cell-like transcription factors. These factors functionally cooperate to promote transcriptional up-regulation of key mTOR pathway components and of metastasis mediators. Their expression is also associated with stem cell-like and metastasis signatures in tumors, and their depletion impairs the metastatic potential of breast cancer cells.Whether an aggressive phenotype is promoted through adaptation or resistance to target inhibition remains poorly understood. Here, complementary studies in human tumors, xenograft models and cell lines reveal transcriptional reprogramming that supports metastasis in response to PI3K/mTOR inhibition. This feature is driven by stem cell-like transcription factors. These factors functionally cooperate to promote transcriptional up-regulation of key mTOR pathway components and of metastasis mediators. Their expression is also associated with stem cell-like and metastasis signatures in tumors, and their depletion impairs the metastatic potential of breast cancer cells.
Citation Format: Pujana MA, Mateo F, Arenas EJ, Gomis R. Stem cell-like transcriptional reprogramming in metastatic resistance [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-07-09.
Abstract P5-08-09: Use of oral contraceptives and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: An international prospective cohort study; for the studies of EMBRACE, GENEPSO, HEBON, kConFab and BCFR
Authors: Schrijver LH , Olsson H , Antoniou AC , Milne RL , Phillips K-A , Andrieu N , Easton DF , Goldgar D , Engel C , Kast K , Roos-Blom M-J , Mooij TM , Hopper JL , van Leeuwen FE , Terry M-B , Rookus MA 
Published: March 2017

Abstract
This abstract was withdrawn by the authors.
Abstract P5-08-17: Breast cancer in octagenerians: A community hospital experience
Authors: Gadiyaram V , Caldwell D 
Published: March 2017

Abstract
Background : Breast cancer incidence increases with age. However Elderly patients are undertreated and underdiagnosed affecting their overall survival with limited availabilty of clinical trial data
Patients and Methods : We used the data from our cancer registry to evaluate the cases of breast cancer diagnosed between the years 2005-2010 with follow up data available to date to examine the method of diagnosis(mammogram vs palpable abnormality ), Age at diagnosis, Stage at diagnosis, Type of surgery (BCT Vs Mastectomy ), Receptor status(ER/PR/Her 2 neu) and treatment's received ( Hormonal therapy , Radiation therapy and chemotherapy) and average survival after the diagnosis of breast cancer. Data regarding the causality of death was not readily available as part of the registry data.
Results : A total of 495 breast cancer cases diagnosed in the years between 2005-2010 wee identified ., Median age at diagnosis was 85 with ages ranging from 81-102 .Out of the 495 patients 55 % were diagnosed with a mammogramand 41 % by palpable abnormality. Patients were diagnosed at Stage 0,1,2,3,4 (12%,45 %,7% ,3 %. 55% underwent Lumpectomy and 31 % underwent Mastectomy .82 % and 18 % ER negative. Her 2 data was only available in 59 patients, out of those tested only 4 Her 2 positive. , Radiation(34 %) /Chemo(6 %)/ Hormone(34%) ,Radiation/Chemo 2 % ,Radiation/Hormone 18%, Chemo/Hormon 2% , 41 % didn't proceed with any treatments.Median survival was 54 months and Average survival was 56 months. Median survival 54 months and average survival was 56 months, With 203 patients alive at the end of 5 years with mortality of about 62 %. However we do not have the data of causality of death in these patient .
Comparison between Age Groups : See table below
Comparision of data b/n Age groupsAge at Diagnosis80-8485-8990 +No of patients24419256Mammogram13810532Palpable Lump947924Lumpectomy1576724Mastectomy803026Average Survival in months84.54848.5
Conclusion: Even though Surgery was performed in most the patients , Only 50 % or lesser number of patients had Adjuvant treatment with Endocrine , Radiation and chemotherapy. Based on the data even though most patient were diagnosed with early stage breast cancer , had significantly poor survival with median survival of about 54 months . With Survival dramatically dropped from 84 months to 48 months in patient 85 + years of age.
Citation Format: Gadiyaram V, Caldwell D. Breast cancer in octagenerians: A community hospital experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-17.
Abstract P5-08-21: The effect of family history on screening procedures and prognosis in breast cancer patients – Results of a large population-based case–control study on breast cancer
Authors: Seiffert K , Thoene K , zu Eulenburg C , Rudolph A , Schmalfeldt B , Flesch-Janys D , Chang-Claude J , Witzel I 
Published: March 2017

Abstract
Background:
Patients with a first- or second-degree family history of breast or ovarian cancer participate more frequently in breast cancer screening procedures. A benefit of additional screening visits has been documented in high-risk patients with (e.g. BRCA 1, BRCA 2 gene mutations). However, the potential benefit of additional screening examinations in moderate risk patients (patients with a history of breast cancer in one or two family members) remains unclear.
Methods:
Patients were recruited in 2002–2005 within a large population-based case–control study on breast cancer in Germany (3,813 cases and 7,341 age-matched healthy controls). Univariate and multivariate analyses were performed to evaluate the effect of family history on breast cancer risk, participation in screening procedures, tumor size and prognosis.
Results
A higher breast cancer risk was observed in patients with a positive family history (1 affected family member: OR 1.32, p&lt;0.001). Patients with a 1st degree positive family history received a higher number of mammograms (MG) (&gt;10 MG: 42.7% vs. 24.9%, p&lt;0.001) and showed a higher rate of imaging-detected tumors (mammogram or ultrasound) (45.8% vs. 31.9%, p&lt;0.001) compared to patients without positive family history. Positive family history (OR 1.45 pT1 vs. ≥pT2, p&lt;0.001) and higher number of mammograms (≥10 mammograms: OR 2.29 pT1 vs. ≥pT2) were associated with smaller tumor size at initial diagnosis. Additionally, there was a significant association between mammogram regularity (HR 0.72, p&lt;0.001) and imaging-assisted tumor detection (HR 0.66, p&lt;0.001) with improved overall survival. However, no significant association between a positive family history of breast cancer and survival could be seen.
Discussion:
Patients with a family history of breast cancer participated more frequently in screening procedures and had a higher rate of image-detected tumors with smaller size at initial diagnosis, compared to patients without affected family members. Breast cancer screening procedures were significantly associated with improved survival.
Citation Format: Seiffert K, Thoene K, zu Eulenburg C, Rudolph A, Schmalfeldt B, Flesch-Janys D, Chang-Claude J, Witzel I. The effect of family history on screening procedures and prognosis in breast cancer patients – Results of a large population-based case–control study on breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-21.
Abstract P5-11-05: Examining bone degeneration as a side effect of treatment in premenopausal breast cancer patients
Authors: Kim M , Kim HJ 
Published: March 2017

Abstract
Background: Although it is widely known that adjuvant treatments cause osteoporosis in postmenopausal women, the effect of treatment and the exact degree of bone loss in premenopausal women is not well understood. For this reason, this study examined the relationship between the changes of bone mineral density(BMD) and the types of treatment in premenopausal breast cancer patients.
Method: This retrospective study looks at preoperative and annual spine bone densitometry tests conducted on breast cancer patients during their observational period following initial treatment for their diagnosis. 461 premenopausal patients who received treatment from January 2006 to April 2007 were the study cohort because of the availability of bone mineral density (BMD) data (L-spine and femur T scores) for a two-year period. The data from the patients were separated into groups according to their treatment plans: observation, adjuvant chemotherapy, adjuvant chemotherapy followed by use of Tamoxifen, and GnRHa(Gonadotropin Releasing Hormone agonist) followed by Tamoxifen.
Results: Of the 461 patients, 21 received no treatment aside from surgery, 75 received only Tamoxifen, 34 only chemotherapy, 166 chemotherapy and Tamoxifen, and 165 Zoladex and Tamoxifen. The no treatment group demonstrates the standard annual change in BMD. At first year, the chemotherapy only group and tamoxifen after chemotherapy group showed significant bone loss in the first year (p&lt;0.005, both). The patients who received tamoxifen alone or tamoxifen with goserelin showed decrease BMD but not significant. After 2 years, tamoxifen with goserelin group showed significant decreased BMD in both spine and femur (p&lt;0.001, p=0.001, both). Chemotherapy group showed partial recovery from the first year bone loss. Conclusion: The patients who received chemotherapy or GnRHa as treatment showed the greatest degree of bone degeneration but at different periods. However, Tamoxifen used along with these treatments seemed to lessen the extent of bone degeneration. Significant bone loss from hormone treatment occurred two years after surgery as compared to one year for chemotherapy.
Citation Format: Kim M, Kim HJ. Examining bone degeneration as a side effect of treatment in premenopausal breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-05.
Abstract P5-11-06: BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial
Authors: Saghatchian M , Lacas B , Deneuve J , Bouvet N , Mokdad-Adi M , Ghouadni A , Amiel P , Charles C , Boinon D , Delaloge S , Dauchy S 
Published: March 2017

Abstract
This abstract was not presented at the symposium.
Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Authors: Goldfarb SB , Konner J , Stevens J , Brouwer S , Narain NR , Ye R , Ravipaty S , Sarangarajan R , Akmaev VR , Jimenez JJ , Belum VR , 'Kitts S , Ciccolini K , Berman B , Lacouture ME 
Published: March 2017

Abstract
Background: Chemotherapy induced alopecia (CIA) may lead to significant psychosocial and quality of life issues. Currently there are no FDA approved oral or topical agents available to prevent CIA. In murine studies, topical calcitriol reduced CIA, due to arrest of cell cycle in healthy hair follicles, and reduction in the sensitivity of follicular epithelium to chemotherapy.
Methods: A prospective dose escalation study is being performed in up to 31 women with breast cancer, gynecologic cancer and sarcomas. Each patient is applying 1mL of BPM31543 to her scalp bid, ≥ 5 days prior to initiation of taxane-based chemotherapy for at least 3 months or until the completion of chemotherapy. The study cohorts are: 5/10/20/40/60/80μg/mL. The first 5 cohorts are completely enrolled and the final cohort is currently being enrolled. Each patient undergoes pk analysis, adverse event (AE) monitoring, patient self-assessment diaries (1-10 scale), and blinded photographic assessments. Efficacy and pK data are still being collected and analyzed for the patients on study, but will be available by December.
Results: Twenty-four subjects have been enrolled so far (evaluable at this time, n = 13). Pk data (n = 16; 5-40μg/mL) showed inter-individual variability, but no significant dose-dependent increase in systemic absorption (range, &lt; 20-110 pg/mL). Treatment-related AEs (probably/possibly) were mild/moderate in nature and included scalp pain (n = 1; 5 μg/mL), elevated vitamin D levels in 1 patient (20μg/mL) and passage of renal calculus in another (n = 1; 40μg/mL). All subjects reported changes in overall hair fullness, thickness, and volume of hair during chemotherapy. At the 5/10 μg/mL dose level, ≥ 75% hair loss was reported in 85% of patients. At the ≥ 20 μg/mL dose level, ≥ 75% hair loss was seen only in 43% of patients. Hair loss/ thinning caused all subjects to change their hair style (onset, week 2; peak, weeks 5-6).
Conclusions: Data have shown that the twice daily application of BPM31543 in patients receiving taxane-based chemotherapy was safe and well-tolerated. Efficacy data from the preliminary analysis was promising and led to the amendment of the study to evaluate two additional higher dose cohorts: 60 and 80 μg/ml.
Citation Format: Goldfarb SB, Konner J, Stevens J, Brouwer S, Narain NR, Ye R, Ravipaty S, Sarangarajan R, Akmaev VR, Jimenez JJ, Belum VR, 'Kitts S, Ciccolini K, Berman B, Lacouture ME. A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-11.
Abstract P5-15-18: MERIBEL STUDY: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
Authors: Ortega V , Antón A , Garau I , Afonso N , Calvo L , Fernández Y , Martinez-Garcia M , Blanco E , Zamora P , García M , Illarramendi JJ , Rodríguez CA , Aguirre E , Pérez J , Cortés J , Llombart A 
Published: March 2017

Abstract
This abstract was withdrawn by the authors.
Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)
Authors: Schneeweiss A , Möbus V , Tesch H , Hanusch C , Denkert C , Lübbe K , Huober J , Klare P , Kümmel S , Untch M , Kast K , Jackisch C , Ingold-Heppner B , Thomalla J , Blohmer J-U , Rezai M , Nekljudova V , von Minckwitz G , Loibl S 
Published: March 2017

Abstract
This abstract was withdrawn by the authors.
Abstract P5-16-25: Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy
Authors: Park S , Lee JS , Kim JH , Lim SM , Park HS , Kim SI 
Published: March 2017

Abstract
Background:According to prior studies, the role of serum vitamin D3 has been inconsistentand clinical implications of 25-hyrdoxyvitamin D (25-OHD) have been little studiedin breast cancer patients receiving neoadjuvant chemotherapy (NCT).
Objectives: The aims of study were to investigate changes in 25-OHD levels before and after NCT and to determine the association of 25-OHD and oncologic outcomes including pathological complete response (pCR) in breast cancer patients.
Patients and Materials: From January 2010 to December 2013, serum 25-OHD levels at pre- and post-NCT were measured in 377 breast cancer patients. The association of serum 25-OHD levels with clinicopathological data including breast cancer subtypes, pCR and survival were retrospectively analysed. Delta 25-OHD was calculated as serum 25-OHDlevels before minus after NCT.
Results: Mean ageof study population was 48.7 yearsand mean follow-up periods were 35.9months.Mean baseline serum 25-OHD concentration was 14.60 ng/mL (standard deviation, 7.44) and more than 80% of patients showed insufficient 25-OHD levels. The mean 25-OHDat post-NCT was 12.16 ng/mL (standard deviation, 6.87).There was a significant decrease in serum 25-OHD after NACT (p&lt;0.001).The pCR rates were 25.7% among study cohort.However, 25-OHD levels at baseline and post-NCT were not related to pCR and survival outcomes. No associations were found between pCR and delta 25-OHD. According to stratification by breast cancer subtypes, however, patients with ≥ -2.67 (median value) of delta 25-OHD revealed a trend of higher achievement of pCR and better survival in luminal A subtype. No associations were found among the other subtypes.
Conclusions: Many Korean breast cancer patients showed insufficient serum 25-OHD levels at diagnosis of malignancy and a significant decrease in serum vitamin D3 after NACT was observed.No significant association of 25-OHD 3 with pCR and survival was found. Therefore, correction or maintenance of appropriate serum 25-OHD levels should be focused for bone health as comprehensive management of breast cancer during NCT.In addition, possible oncological aspects of 25-OHD should further researched individually considering breast subtypes.
Citation Format: Park S, Lee JS, Kim JH, Lim SM, Park HS, Kim SI. Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-25.
Abstract P5-16-26: National trends in neoadjuvant therapy for breast cancer
Authors: Schnabel F , Schwartz S , Hochman T , Chun J , Goldberg J 
Published: March 2017

Abstract
Purpose:Neoadjuvant therapy has been widely integrated in the treatment of locally advanced breast cancer. Over time, this strategy has been extended to include patients with earlier stage disease to allow for assessment of in vivo response to treatment. The aim of this study was to describe the national trends in neoadjuvant therapy for all invasive breast cancers with a particular focus on triple negative disease and HER2 status.
Methods: The National Cancer Database (NCDB), an oncology outcomes database that collects data from more than 1500 Commission on Cancer (CoC) accredited cancer programs, was queried for all women diagnosed with invasive breast cancer from 2006-2013. Patients with unknown systemic therapy sequence were excluded. Women were classified by whether or not they received neoadjuvant systemic, chemo and/or endocrine, therapy.
Results: We identified 1,221,976 cases that were eligible for this analysis. Of these, 29.7% were HER2 negative, 18.4% were classified as triple negative, and 8.9% received neoadjuvant systemic therapy. The percentage of patients receiving neoadjuvant therapy increased from 7.5% in 2006 to 9.8% in 2012 with a slight decrease to 9.5% in 2013. This increase in the use of neoadjuvant therapy over the time period was statistically significant (p&lt;0.0001). There was a small increase in the percent of patients with HER2 positive status who received neoadjuvant therapy, from 5.7% in 2006 to 6.5% in 2013. During this time period, there was a 9% increase in the percent of triple negative patients who received neoadjuvant therapy (13.1% in 2016 to 22.1% in 2013).
Number and percent of patients who received/did not receive neoadjuvant therapy by year2006 (N=136117)2007 (N=143033)2008 (N=148888)2009 (N=154713)2010 (N=154040)2011 (N=162333)2012 (N=163395)2013 (N=159457)No Neoadjuvant Therapy | 125908 (92.5)131559 (91.98)136593 (91.74)141364 (91.37)139459 (90.53)146500 (90.25)147401 (90.21)144306 (90.5)Neoadjuvant Therapy | 10209 (7.5)11474 (8.02)12295 (8.26)13349 (8.63)14581 (9.47)15833 (9.75)15994 (9.79)15151 (9.5)
Conclusions: Over the time period from 2006-2013, there has been an apparent increase in the percentage of patients who received neoadjuvant therapy. This trend is accompanied by increases in the percentage of TNBC patients and in Her2 positive patients who received neoadjuvant therapy. Other factors and the joint effects of these factors on the observed increase in the use of neoadjuvant therapy are under evaluation to elucidate the basis for this observation in the NCDB data.
Citation Format: Schnabel F, Schwartz S, Hochman T, Chun J, Goldberg J. National trends in neoadjuvant therapy for breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-26.
Abstract P6-01-08: Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer
Authors: Powell E , Shao J , Tieu T , Peoples M , Bristow C , Manyam G , Cai S , Tu Y , Edwards JR , Heffernan TP , Piwnica-Worms D , Liang H , Piwnica-Worms H 
Published: March 2017

Abstract
Metastases are responsible for the vast majority of deaths due to breast cancer. Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of metastasis and poor response to chemotherapy. We are using patient derived xenograft (PDX) models of TNBC to identify drivers of TNBC metastasis. Using these models, we demonstrated that human breast tumors are capable of completing all stages of the metastatic cascade in mice, and metastatic lesions are observed in organs normally found in patients with metastatic breast cancer including lung, liver, bone, brain and lymph nodes. Lentiviral transduction was employed to express both bioluminescent and fluorescent proteins in three distinct PDX models of TNBC. In this way, metastatic lesions can be isolated using bioluminescent imaging and circulating tumor cells (CTCs) are isolated by flow cytometry. A lung metastasis gene expression signature was generated and comprehensive gain-of-function screens are being conducted in vivo to validate this signature and identify functional drivers of TNBC metastasis.
Citation Format: Powell E, Shao J, Tieu T, Peoples M, Bristow C, Manyam G, Cai S, Tu Y, Edwards JR, Heffernan TP, Piwnica-Worms D, Liang H, Piwnica-Worms H. Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-01-08.